公司董事吴宏豪先生就上述情况作出书面说明如下：公司于 2025 年 8 月 26 日、 2025 年 10 月 28 日召开第二届董事会第九次会议、第二届董事会第十次会 议，本人因公务原因，连续两次未能亲自出席董事会会议，已委托董事周宏策先 生代表本人出席上述会议，本人对上述董事会会议作出的决议均无异议。 特此公告。 证券代码：301602 证券简称：超研股份 公告编号：2025-051 汕头市超声仪器研究所股份有限公司 关于董事连续两次未亲自出席董事会会议的说明 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 汕头市超声仪器研究所股份有限公司（以下简称"公司"）分别于 2025 年 8 月 26 日、 2025 年 10 月 28 日召开了第二届董事会第九次会议、第二届董事会 第十次会议，公司董事吴宏豪先生因公务原因连续两次未亲自出席上述董事会会 议，委托董事周宏策先生出席并表决。 根据《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 范运作（2025 年修订）》第 3.3.4 规定"连续两次未亲自出席董事会会议，董 事应当作出书面说明并对 ...

Core Viewpoint - The company, Chaoyan Co., Ltd., has experienced a decline in stock performance and financial metrics, indicating potential challenges in its operational performance and market position [1][2]. Financial Performance - As of September 30, 2025, Chaoyan Co., Ltd. reported a revenue of 254 million yuan, a year-on-year decrease of 2.90% [2]. - The net profit attributable to shareholders for the same period was approximately 88.94 million yuan, reflecting a decline of 3.66% year-on-year [2]. - Cumulative cash dividends distributed since the company's A-share listing amount to approximately 43.69 million yuan [2]. Stock and Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 23.90% to 17,000, while the average number of circulating shares per shareholder increased by 39.99% to 3,438 shares [2]. - The total financing balance for Chaoyan Co., Ltd. is approximately 96.65 million yuan, accounting for 6.63% of its market capitalization [1]. Institutional Holdings - The largest circulating shareholder is Huabao Zhongzheng Medical ETF, holding 1.5245 million shares, which decreased by 388,200 shares compared to the previous period [3]. - New institutional shareholders include Yuanxin Yongfeng Medical Health A, holding 650,100 shares, and Medical Device ETF, holding 350,100 shares [3]. - Other notable changes include Hong Kong Central Clearing Limited increasing its holdings by 62,000 shares to 532,000 shares [3].

Group 1 - The company, Chao Yan Co., reported a revenue of approximately 254 million yuan for the first three quarters of 2025, representing a year-on-year decrease of 2.9% [1] - The net profit attributable to shareholders of the listed company was approximately 88.94 million yuan, a year-on-year decrease of 3.66% [1] - The basic earnings per share were 0.21 yuan, reflecting a year-on-year decrease of 16% [1]

Core Viewpoint - Chao Yan Co., Ltd. (301602.SZ) reported a decline in revenue and net profit for the first three quarters of 2025 compared to the previous year [1] Financial Performance - The company achieved an operating income of 254 million yuan, a year-on-year decrease of 2.90% [1] - The net profit attributable to shareholders was 88.94 million yuan, reflecting a year-on-year decrease of 3.66% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 81.19 million yuan, showing a slight decrease of 0.03% year-on-year [1] - Basic earnings per share stood at 0.21 yuan [1]

中国银河证券股份有限公司 关于汕头市超声仪器研究所股份有限公司 使用募集资金置换投入募投项目自筹资金 的核查意见 中国银河证券股份有限公司（以下简称"银河证券"或"保荐人"）作为汕头市 超声仪器研究所股份有限公司（以下简称"公司"或"超研股份"）首次公开发行股 票并上市的保荐人，根据《证券发行上市保荐业务管理办法（2025 修正）》《深圳证 券交易所创业板股票上市规则（2025 年修订）》《深圳证券交易所上市公司自律监管 指引第 2 号——创业板上市公司规范运作（2025 年修订）》《上市公司募集资金监管 规则》等有关规定，对超研股份使用募集资金置换投入募投项目自筹资金事项进行了 审慎核查，发表核查意见如下： 一、募集资金的基本情况 经中国证券监督管理委员会《关于同意汕头市超声仪器研究所股份有限公司首次 公开发行股票注册的批复》（证监许可〔2024〕1391 号）同意注册，公司已完成首次 公开发行人民币普通股（A 股）64,249,446 股，每股发行价格 6.70 元，募集资金总额 为人民币 430,471,288.20 元，扣除发行费用 46,108,086.88 元（不含税），公司实际募 集资金净额为人 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 汕头市超声仪器研究所股份有限公司（以下简称"公司"）于 2025 年 10 月 28 日召开第二届董事会第十次会议，审议通过了《关于使用募集资金置换投入 募投项目的自筹资金的议案》，同意公司使用募集资金置换投入募投项目的自筹 资金。现将有关情况公告如下： 一、募集资金的基本情况 经中国证券监督管理委员会《关于同意汕头市超声仪器研究所股份有限公司 首次公开发行股票注册的批复》（证监许可〔2024〕1391 号）同意注册，公司已 完成首次公开发行人民币普通股（A 股）64,249,446 股，每股发行价格 6.70 元， 募集资金总额为人民币 430,471,288.20 元，扣除发行费用 46,108,086.88 元（不 含税），公司实际募集资金净额为人民币 384,363,201.32 元，募集资金已于 2025 年 1 月 17 日划至公司指定账户。华兴会计师事务所（特殊普通合伙）对公司本 次公开发行股票的资金到位情况进行了审验，并于 2025 年 1 月 17 日出具了《验 资报告》（华兴验字〔2025〕2 ...

汕头市超声仪器研究所股份有限公司 第二届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 汕头市超声仪器研究所股份有限公司（以下简称"公司"）第二届董事会第 十次会议于 2025 年 10 月 28 日以现场方式在汕头市龙江路 3 号汕头市超声仪器 研究所股份有限公司 1 楼会议室召开。此前公司于 2025 年 10 月 17 日以电子邮 件、微信、电话等方式向全体董事发出会议通知。 本次会议应出席董事 9 人，实际出席董事 9 人（其中：委托出席的董事人数 1 人），董事吴宏豪先生因公务无法亲自出席会议，委托董事周宏策先生出席会 议。公司部分高级管理人员列席了本次会议。会议由董事长李德来先生主持。本 次董事会会议的召集、召开和表决程序符合《中华人民共和国公司法》《中华人 民共和国证券法》等法律、法规、规范性文件和《公司章程》的相关规定。 证券代码：301602 证券简称：超研股份 公告编号：2025-048 2、审议通过《关于使用募集资金置换投入募投项目的自筹资金的议案》。 经审议，董事会认为：公司使用募集资金 ...

Financial Performance - The company's operating revenue for Q3 2025 was ¥69,929,018.69, a decrease of 31.07% compared to the same period last year[4] - Net profit attributable to shareholders was ¥20,499,021.09, down 40.69% year-on-year[4] - The basic earnings per share decreased by 44.44% to ¥0.05, while diluted earnings per share also fell by 44.44% to ¥0.05[4] - Total revenue for the current period is ¥253,606,900.34, a decrease of 2.16% from ¥261,170,540.28 in the previous period[18] - Net profit for the current period is ¥88,944,481.22, down 3.66% from ¥92,321,637.60 in the previous period[19] - The total comprehensive income for the current period is ¥89,342,559.55, a decrease from ¥92,491,503.99 in the previous period, reflecting a decline of approximately 3.7%[20] - Basic and diluted earnings per share for the current period are both ¥0.21, down from ¥0.25 in the previous period, representing a decrease of 16%[20] Assets and Liabilities - Total assets increased by 40.39% to ¥1,412,413,645.76 compared to the end of the previous year[4] - Current assets rose to ¥1,288,085,508.61, up 46.49% from ¥879,665,743.61 at the beginning of the period[16] - Total liabilities decreased to ¥110,843,896.09 from ¥135,377,063.86, a decline of 18.14%[17] - The company's equity increased significantly to ¥1,301,569,749.67 from ¥870,660,773.85, marking a growth of 49.43%[17] Cash Flow - Cash flow from operating activities for the year-to-date was ¥63,080,448.02, down 8.03%[4] - Cash inflow from operating activities totaled ¥323,042,024.98, an increase from ¥258,619,893.23 in the previous period, marking a growth of approximately 25%[21] - Net cash flow from operating activities is ¥63,080,448.02, down from ¥68,588,538.39 in the previous period, indicating a decline of about 8%[21] - Cash inflow from investment activities is ¥1,572,662,164.31, a decrease from ¥2,357,317,461.91 in the previous period, reflecting a decline of approximately 33%[22] - Net cash flow from investment activities is -¥23,375,488.23, worsening from -¥5,673,376.00 in the previous period[22] - Cash inflow from financing activities is ¥401,633,651.91, with cash outflow for dividend distribution and interest payments totaling ¥43,689,590.81[22] - The net increase in cash and cash equivalents for the current period is ¥375,611,864.95, compared to an increase of ¥58,039,045.05 in the previous period[22] - The ending balance of cash and cash equivalents is ¥578,090,968.49, significantly higher than ¥152,580,166.72 in the previous period[22] Shareholder Information - The total number of common shareholders at the end of the reporting period is 16,970[9] - The largest shareholder, Shantou Ultrasonic Asset Management Co., Ltd., holds 51.32% of shares, totaling 219,830,247 shares[9] - The second-largest shareholder, Shantou Municipal Government State-owned Assets Supervision and Administration Commission, holds 31.14% of shares, totaling 133,369,945 shares[9] - The top ten shareholders collectively hold a significant portion of the company's shares, with the top three alone accounting for over 84%[9] - The company has no preferred shareholders as of the reporting period[11] - There are no changes in the number of restricted shares for the major shareholders during the reporting period[12] - The total number of restricted shares at the end of the period is 369,975,714 shares[13] - The company plans to release some restricted shares in 2026, with specific dates for each shareholder[12] - The company has not reported any related party transactions among the top shareholders[10] Operational Insights - The company received government subsidies amounting to ¥5,359,015.20 during the reporting period[5] - Accounts receivable decreased by 50.92% to ¥23,717,480.19, primarily due to the collection of receivables[7] - Inventory increased by 37.66% to ¥149,882,508.32, mainly due to increased reserves of imported raw materials[8] - Research and development expenses for the current period were ¥39,350,225.93, an increase of 8.63% compared to ¥36,954,438.09 in the previous period[18] - The company reported a financial income of ¥18,894,748.75, which is an increase from ¥8,715,395.36 in the previous period[18] - The fair value change loss was recorded at -¥258,786.86, compared to a loss of -¥1,263,030.84 in the previous period, indicating an improvement[19] - The company has a strategic plan for future growth, focusing on market expansion and new product development[14] Audit Status - The company has not undergone an audit for the third quarter financial report[23]

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., is engaged in the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, benefiting from the pet economy and the depreciation of the RMB [2][3]. Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. was established on November 15, 1982, and went public on January 22, 2025. It is a national key high-tech enterprise focusing on medical imaging and industrial non-destructive testing equipment [7]. - The company's main business revenue composition includes: medical ultrasound 71.16%, industrial ultrasound 17.30%, accessories 5.72%, X-ray 4.56%, and others 1.26% [7]. Financial Performance - For the first half of 2025, the company achieved operating revenue of 184 million yuan, a year-on-year increase of 15.00%, and a net profit attributable to shareholders of 68.45 million yuan, up 18.50% year-on-year [8]. - As of June 30, 2025, the company's overseas revenue accounted for 55.26%, benefiting from the depreciation of the RMB [3]. Market Activity - On October 28, the company's stock rose by 0.76%, with a trading volume of 57.19 million yuan and a turnover rate of 3.90%, bringing the total market capitalization to 10.755 billion yuan [1]. - The stock has seen a net outflow of 1.2384 million yuan from major funds today, with a continuous reduction in major fund positions over the past three days [4][5]. Product and Innovation - The company showcased its innovative veterinary medical imaging achievements at the 97th WVC annual meeting, focusing on pets, horses, and livestock, and engaged with industry experts on animal healthcare development [2]. - The company has developed a "Hongyun" system for portable ultrasound and DR devices that utilizes 5G networks for remote image transmission and interaction, enhancing the development of portable devices [2].

Core Viewpoint - Chao Yan Co., Ltd. has shown a stable financial performance with a notable increase in revenue and net profit, while also experiencing changes in shareholder structure and trading activity [1][2][3]. Financial Performance - For the first half of 2025, Chao Yan Co., Ltd. achieved operating revenue of 184 million yuan, representing a year-on-year growth of 15% [2]. - The net profit attributable to shareholders reached 68.45 million yuan, marking an 18.5% increase compared to the previous period [2]. Shareholder Structure - As of June 30, 2025, the number of shareholders decreased by 16.65% to 22,300, while the average circulating shares per person increased by 19.98% to 2,456 shares [2]. - The top circulating shareholder is Huabao Zhongzheng Medical ETF, holding 1.91 million shares as a new shareholder [3]. - Other notable new shareholders include Southern Zhongzheng 1000 ETF and Huaxia Zhongzheng 1000 ETF, indicating a shift in institutional holdings [3]. Trading Activity - On October 27, 2023, Chao Yan Co., Ltd. experienced a slight decline of 0.36% in stock price, with a trading volume of 50.21 million yuan [1]. - The financing buy-in amount for the day was 7.87 million yuan, with a net buy of 5.14 million yuan after repayments [1]. - The total margin trading balance reached 97.31 million yuan, with financing accounting for 6.68% of the circulating market value [1].